

USSN: 09/350,202


DRAFT

Claim 57. (Currently Amended): The method of claim 50, further comprising: monitoring proliferation of the T cells; and

reactivating and re-stimulating the T cells with the first <u>agent</u> and second agents the anti-CD28 antibody when the rate of T cell proliferation has decreased to induce further proliferation of the T cells.

Claim 58. (Previously Added): The method of claim 57, wherein the step of monitoring proliferation of the T cells is by examining cells size or determining the level of expression of a cell surface molecule, and the step of reactivating and restimulating is initiated when T cell size has decreased or when the level of the cell surface molecule has decreased.

Claim 59. (Previously Cancelled)



USSN: 09/349,915

DRAFT

PROPOSED AMENDMENTS TO USSN:09/349,915

Claim 1 (Cancelled): A method for inducing a population of T cells to proliferate to sufficient numbers for use in therapy, comprising:

- a) activating a population of T cells; and
- b) stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule, the activating and stimulating steps thereby inducing proliferation of the T cells to sufficient numbers for use in therapy.

Claims 2-49 (Cancelled)

Claim 50 (Currently Amended): A method for inducing ex vivo proliferation of a population of T cells, comprising contacting a population of T cells ex vivo with a solid phase surface having directly immobilized thereon:

- (a) a first agent which provides a primary activation signal to the T cells, thereby activating the T cells; and
- (b) a second agent an anti-CD28 antibody which stimulates an accessory molecule on the surface of the T cells, thereby stimulating the activated T cells, the first agent and second agents the anti-CD28 antibody thereby inducing the T cells to proliferate.

Claim 51 (Previously Added): The method of claim 50, wherein the first agent stimulates a TCR/CD3 complex-associated signal in the T cells.

Claim 52 (Previously Added): The method of claim 50, wherein the first agent is an anti-CD3 antibody.

Claim 53 (Previously Added): The method of claim 52, wherein the anti-CD3 antibody is an anti-human CD3 monoclonal antibody.

Claim 54 (Previously Added): The method of claim 50, wherein the accessory molecule on the T cell is CD28.



USSN: 09/349,915

DRAFT

Claim 55 (Cancelled): The method of claim 54, wherein the second agent is an anti-CD28 antibody.

Claim 56 (Currently Withdrawn)

Claim 57 (Currently Amended): The method of claim 50, further comprising:

monitoring proliferation of the T cells; and

reactivating and restimulating the T cells with the first agent and second agents the anti-CD28 antibody when the rate of T cell proliferation has decreased to induce further proliferation of the T cells.

Claim 58 (Previously Added): The method of claim 57, wherein the step of monitoring proliferation of the T cells is by examining cell size or determining the level of expression of a cell surface molecule, and the step of reactivating and restimulating is initiated when T cell size has decreased or when the level of the cell surface molecule has decreased.

Claim 59 (Currently Withdrawn)

Unofficial